drugset / Trial / NCT01109680

A Single Center, Open-Label Study to Quantify Metabolites of [14C]-Neramexane in Plasma and Urine in Healthy Male Subjects

NCT01109680 ↗

Phase 1 Completed 8 enrolled Merz Pharmaceuticals GmbH
NaSingle-groupOpen-labelBasic science

Summary

A Single Center, Open-Label Study to quantify metabolites of \[14C\]-Neramexane in plasma and urine in Healthy Male Subjects

Timeline

Start
2010-04
Primary completion
2010-06
Completion
2010-06

Drugs

EvaluationDrugModalityDoseRoute
Subject Neramexane Small molecule — —

Indications

No indication recorded.